特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

無細胞タンパク質発現の世界市場:成長、動向、および予測(2019年~2024年)

Cell-free Protein Expression Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 708600
出版日 ページ情報 英文 105 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.17円で換算しております。
無細胞タンパク質発現の世界市場:成長、動向、および予測(2019年~2024年) Cell-free Protein Expression Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年11月01日 ページ情報: 英文 105 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートは世界の無細胞タンパク質発現市場について調査しており、市場機会や動向、成長および阻害要因、製品・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
    • プロテオミクス・ゲノミクスの分野における研究開発の増加
    • 癌・感染症の高い有病率
    • 発現時間の短縮および構造の修正
  • 阻害要因
    • 高いコスト
    • 翻訳後の修正のための効果的なシステムの欠如
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 製品別
    • 付属品・消耗品
    • 溶解物システム
  • 用途別
    • 酵素工学
    • ハイスループット生産
    • タンパク質標識
    • タンパク質間相互作用
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Biotechrabbit GmbH
    • CellFree Sciences Co. Ltd
    • Cube Biotech GmbH
    • GeneCopoeia Inc.
    • Jena Bioscience GmbH
    • Promega Corporation
    • Qiagen NV
    • Sigma-Aldrich Corporation (Merck KGaA)
    • タカラバイオ株式会社
    • Thermo Fisher Scientific Inc.

第7章 市場機会および今後の動向

目次
Product Code: 64246

Market Overview

The major factors for the growth of the cell-free protein expression market include the increasing R&D in the fields of proteomics and genomics, high prevalence of cancer and infectious diseases, and shorter expression time and structural modification.

Cell-free protein expression employs cell lysates for the production of the desired recombinant proteins, with the primary advantage of this technique being the aversion of workflow hurdles of maintaining cell culture or living cells. Cell lysates are produced by breakdown and use of cellular components of eukaryotic or bacterial cells. Currently, several cell-free protein expression systems are commercially available, based on E. coli, rabbit reticulocytes, wheat germs, human cell lines, and insect cells. In vitro protein expression system has significant advantages over living cell-based protein expression, including a shorter duration of the process, isotopic labeling of proteins, incorporation of non-natural amino acids, and optimization of protein complexes. Pertaining to the recent trend of more research in personalized medicine and growing needs for biological therapies for the management of cancers, the ability to enable high throughput production is a major driver for the adoption of cell-free protein expression techniques by pharmaceutical and biotechnology firms.

Scope of the Report

As per the scope of this report, cell-free protein expression or in vitro protein synthesis is a process that involves the production of the recombinant proteins in cell lysate solution, without using cell culture or living cells. Cell-free protein expression can be carried out using different cell lysates, such as those of E. coli, rabbit reticulocytes, wheat germs, human cells, and insect cells.

Key Market Trends

E. Coli Lysate is the Segment by Lysate Systems is expected to be the Fastest Growing Segment Over the Forecast Period

E. coli lysates are the most commonly used systems among all available commercial lysate systems. E. coli lysates are devoid of endogenous genetic messages and have advantages, such as very high protein yield and tolerability to most additives. Furthermore, E. coli-based systems are being used in recombinant techniques for the manufacture of various biological therapeutics and insulin. Continuous use has enabled research on interactions and tolerability of by-products of E. coli-based systems, and significant present scientific literature enables its rapid adoption by industries and academics. In E. coli-based systems, codons used are different, with some being eukaryotic specific. Also, post-translational modifications are not possible, which in turn, limit the system's usage in the synthesis of specific human therapeutics. However, significant advancements have been made in order to address these problems. Therefore, the E.coli lysate sub-segment is expected to register a steady growth rate during the forecast period, owing to high adoption rates and recent developments.

North America is Expected to Dominate the Market

North America is found to hold a major share for the cell-free protein expression market and is expected to show a similar trend over the forecast period, without significant fluctuations. The primary factors behind the large market size include the increasing prevalence of chronic diseases, such as cancer, aging population, growing demand for targeted and personalized medicine, the presence of major R&D facilities, and favorable government initiatives in the United States. There is a growing trend of cell-based research in the US academia and biotechnology industries. In recent years, several government initiatives have been launched supplementing the growth of the cell-free protein expression market in the United States. For instance, 2015 saw the introduction of the Precision Medicine Initiative in the United States, which was intended to revolutionize the treatment of many chronic diseases, including cancer. Initiatives like these are presenting a favorable environment for pharmaceutical and biotechnology firms to develop and market protein-based therapeutics, thus, fueling the growth of the cell-free protein expression market.

Competitive Landscape

The market studied is a moderately consolidated market owing to the presence of small and large market players. Some of the market players are biotechrabbit GmbH, CellFree Sciences Co. Ltd, Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Promega Corporation, Qiagen NV, Sigma-Aldrich Corporation (Merck KGaA), Takara Bio Inc., and Thermo Fisher Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing R&D in the Fields of Proteomics and Genomics
    • 4.2.2 High Prevalence of Cancer and Infectious Diseases
    • 4.2.3 Shorter Expression Time and Structural Modification
  • 4.3 Market Restraints
    • 4.3.1 High Cost
    • 4.3.2 Lack of Effective Systems for Post-translational Modifications
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Products
    • 5.1.1 Accessories and Consumables
    • 5.1.2 Lysate Systems
      • 5.1.2.1 E. Coli Lysate
      • 5.1.2.2 Wheat Germ Extract Lysate
      • 5.1.2.3 Rabbit Reticulocyte Lysate
      • 5.1.2.4 Insect Cell Lysate
      • 5.1.2.5 Human Cell Lysate
      • 5.1.2.6 Other
  • 5.2 By Application
    • 5.2.1 Enzyme Engineering
    • 5.2.2 High Throughput Production
    • 5.2.3 Protein Labeling
    • 5.2.4 Protein-Protein Interaction
    • 5.2.5 Other
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biotechrabbit GmbH
    • 6.1.2 CellFree Sciences Co. Ltd
    • 6.1.3 Cube Biotech GmbH
    • 6.1.4 GeneCopoeia Inc.
    • 6.1.5 Jena Bioscience GmbH
    • 6.1.6 Promega Corporation
    • 6.1.7 Qiagen NV
    • 6.1.8 Sigma-Aldrich Corporation (Merck KGaA)
    • 6.1.9 Takara Bio Inc.
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS